Pure Global
NCT06330051

The Improve Acute Reperfusion Treatment Quality for Ischemic Stroke Through Spatiotemporal Computing in China

The Improve Acute Reperfusion Treatment Quality for Ischemic Stroke Through Spatiotemporal Computing in China (IMPROVE-II ) -A Multicenter, Evaluator-Blind, Cluster-Randomized Controlled Study
Beijing Tiantan Hospital·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
improvement acute reperfusion treatment quality for stroke through spatiotemporal computing
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Beijing Tiantan Hospital
Timeline & enrollment
Phase
N/A
Start date
Mar 18, 2024
End date
Apr 20, 2025
Enrollment
600 participants
Primary outcome

The Door to Needle time (DNT) for intravenous thrombolytic therapy in eligible patients within 4.5 hours of onset.

Summary

This study intends to construct the goal-oriented integrated intervention model for AIS
 in-hospital procedure through the spatiotemporal positioning and the P-D-C-A cycle for
 continuous improvement (FAST model). Then a multicenter, evaluator-blind, cluster-randomized
 controlled study aims to verify the validity and safety of this FAST model.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06330051
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06330051 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing Tiantan Hospital and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.